Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Melanoma 29Neoplasms 10Brain Neoplasms 6Neoplasm Metastasis 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Skin Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Lymphoma 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Fever 1Differentiated Thyroid Cancer (DTC) 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

Gemcitabine 18Cisplatin 12Oxaliplatin 7pembrolizumab 6Nivolumab 6Capecitabine 4trametinib 3Fluorouracil 3Bevacizumab 3tremelimumab 2lenvatinib 2durvalumab 2derazantinib 2atezolizumab 2Trastuzumab 2Ramucirumab 2Radiofrequency Ablation 2Panitumumab 2Leucovorin 2Cryosurgery 2zanidatamab 1vandetanib 1tucatinib 1tocilizumab 1telotristat ethyl 1sargramostim 1rucaparib 1regorafenib 1pertuzumab 1milademetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Biliary Tract Neoplasms × dabrafenib × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡